Opinion|Videos|August 30, 2024
Operationalizing Biosimilars in Specialty Pharmacies
Author(s)Sophia Humphreys, PharmD, MHA
Dr. Humphreys discusses operationalizing biosimilars in specialty pharmacies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does the current process look like for switching between reference products and biosimilars and between biosimilars at specialty pharmacies, and how can it be streamlined?
- In states that allow pharmacists to switch to a biosimilar without prior prescriber approval, how effective are automatic substitutions based on interchangeability and collaborative practice agreements?
Advertisement
Related to this article
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Persistent symptoms can complicate life after a multiple myeloma treatment response, making routine symptom assessment and targeted supportive care essential.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Convenience should not replace connection.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
3
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
4
C difficile Survivor and PLF Board Member Describes the Counseling Gap Pharmacists Can Close
5